Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ´º½º·¹ÅÍ > ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö > The Burrill Report (formerly Burrill Biotechnology Report Monthly)
´º½º ·¹ÅÍ Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (10)
ÆÄ¸Ó½´Æ¼Äà (28)
¸ÞµðÄõð¹ÙÀ̽º (7)
Á¤º¸Åë½Å (59)
ÀüÀÚºÎǰ/¹ÝµµÃ¼ (5)
ÀÚµ¿Â÷ (4)
¿¡³ÊÁö (7)
ȯ°æ (4)
¹æÀ§/Ç×°ø/¿ìÁÖ (7)
¸ÅÆ®¸®¾ó (21)
»ê¾÷¿ë±â°è (1)
°ÇÃà/Åä¸ñ (3)
±ÝÀ¶/¹ðÅ· (7)
½Äǰ/À½·á (21)
ÀϹݼҺñÀç (8)
´º½º·¹ÅÍ

The Burrill Report (formerly Burrill Biotechnology Report Monthly)

¸®¼­Ä¡»ç BURRILL & COMPANY
¹ßÇàÀÏ »óǰÄÚµå 74682
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 699 £Ü 832,800 PDF By E-mail (Single User License)
US $ 1,999 £Ü 2,381,800 PDF By E-mail (Single User License)


¿µ¹®¸ñÂ÷

Abstract

In The Burrill Report you will find how life science companies are faring with their cash positions, whether or not the IPO market is returning and what companies are doing about it; how emerging technology promises to revolutionize vaccines, and what's happening in the realm of new antibiotics.

Our regular features include:

  • Venture financings
  • Public Financings
  • Grants
  • Partnering and licensing deals
  • Mergers and acquisitions
  • Nasdaq non-compliance notices and regained compliance
  • FDA new product approvals
  • Upcoming PDFUA dates
  • Layoffs and hirings
  • Executive changes
  • Bankruptcies and liquidations
  • Legal news
  • Patent news
  • Research news

And a rundown on the Burrill family of life science indices.

Back to Top